UM171 is a potent agonist of human hematopoietic stem cell renewal, independently of AhR suppression. UM171 act differently than other small molecule stimulators of hematopoiesis, such as the aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Addition of UM171 to cultures containing SR1 and cytokines further enhances the ex vivo expansion of normal HSCs, including CD34+ cells.

Elpamotide is an anti-angiogenic cancer vaccine. It is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) (RFVPDGNRI) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. OncoTherapy Science was developing elpamotide for the treatment of solid tumors.

Tigapotide (also known as PCK3145) is a synthetic peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the prostate is downregulated in patients with advanced prostate cancer and believed to be a survival mechanism for the cancer cells. Tigapotide can exert anticancer activity not only on prostate but also on breast and colon cancer cells, possibly through laminin receptor-mediated activation of MEK and ERK1/2 phosphorylation. However, the exact molecular mechanisms of action of Tigapotide against prostate cancer tumor growth and metastasis, and tumor-associated angiogenesis remain poorly understood. In preclinical trials, Tigapotide shows potent anticancer activity and reduces prostate cancer growth in PC3 xenograft mouse model and the Dunning rat R-3327 MLL model. Phase II a clinical trial results with Tigapotide confirmed its therapeutic safety and tolerability for metastatic hormone-refractory prostate cancer. This effect was in part correlated to a marked reduction in the high levels of plasma MMP-9, a gelatinase B enzyme involved in extracellular matrix degradation and tumor invasion, of patients receiving Tigapotide, suggesting a biological effect possibly related to control metastasis.

alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.

XG-102 (also known as brimapitide), a D-stereoisomer of a c-Jun-N-terminal kinase-1111 was developed in a biocompatible gel formulation for the treatment of sudden sensorineural hearing loss with a single-dose administration into the middle ear. It’s a cell-penetrating peptide which inhibits the JNK stress kinase. JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in apoptosis of sensory cells as well as in inflammatory responses. By blocking JNK, AM-111 protects stress-injured cochlear cells and helps to prevent or reduce chronic hearing loss. Auris Medical's otoprotective drug AM-111 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of acute sensorineural hearing loss (ASNHL), a condition which may occur following various inner ear injuries. In addition, XG-102 was studied in phase III clinical trials in the treatment of acute inner ear hearing loss and in the reduction of post-cataract surgery intraocular inflammation. Besides, XG-102 is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease.